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Abstract
The PI3K/PTEN/Akt/mTOR pathway plays critical roles in the regulation of cell growth. The effects
of this pathway on drug resistance and cellular senescence of breast cancer cells has been a focus of
our laboratory. Introduction of activated Akt or mutant PTEN constructs which lack lipid phosphatase
[PTEN(G129E)] or lipid and protein phosphatase [PTEN(C124S)] activity increased the resistance
of the cells to the chemotherapeutic drug doxorubicin, and the hormonal drug tamoxifen. Activated
Akt and PTEN genes also inhibited the induction of senescence after doxorubicin treatment; a
phenomenon associated with unrestrained proliferation and tumorigenesis. Interference with the lipid
phosphatase domain of PTEN was sufficient to activate Akt/mTOR/p70S6K as MCF-7 cells
transfected with the mutant PTEN gene lacking the lipid phosphatase activity [PTEN(G129E)]
displayed elevated levels of activated Akt and p70S6K compared to empty vector transfected cells.
Cells transfected with mutant PTEN or Akt constructs were hypersensitive to mTOR inhibitors when
compared with the parental or empty vector transfected cells. Akt-transfected cells were cultured for
over two months in tamoxifen from which tamoxifen and doxorubicin resistant cells were isolated
that were >10-fold more resistant to tamoxifen and doxorubicin than the original Akt-transfected
cells. These cells had a decreased induction of both activated p53 and total p21Cip1 upon doxorubicin
treatment. Furthermore, these cells had an increased inactivation of GSK-3β and decreased
expression of the estrogen receptor-α. In these drug resistant cells, there was an increased activation
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of ERK which is associated with proliferation. These drug resistant cells were hypersensitive to
mTOR inhibitors and also sensitive to MEK inhibitors, indicating that the enhanced p70S6K and
ERK expression was relevant to their drug and hormonal resistance. Given that Akt is overexpressed
in greater than 50% of breast cancers, our results point to potential therapeutic targets, mTOR and
MEK. These studies indicate that activation of the Akt kinase or disruption of the normal activity of
the PTEN phosphatase can have dramatic effects on activity of p70S6K and other downstream
substrates and thereby altering the therapeutic sensitivity of breast cancer cells. The effects of
doxorubicin and tamoxifen on induction of the Raf/MEK/ERK and PI3K/Akt survival pathways were
examined in unmodified MCF-7 breast cells. Doxorubicin was a potent inducer of activated ERK
and to a lesser extent Akt. Tamoxifen also induced ERK. Thus a consequence of doxorubicin and
tamoxifen therapy of breast cancer is the induction of a pro-survival pathway which may contribute
to the development of drug resistance. Unmodified MCF-7 cells were also sensitive to MEK and
mTOR inhibitors which synergized with both tamoxifen and doxorubicin to induce death. In
summary, our results point to the key interactions between the PI3K/PTEN/Akt/mTOR and Raf/
MEK/ERK pathways in regulating chemotherapeutic drug resistance/sensitivity in breast cancer and
indicate that targeting these pathways may prevent drug and hormonal resistance.
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Introduction
Breast cancer ranks as the second most common cause of cancer death among women in the
United States. Only lung cancer, which results primarily from cigarette smoking, induces more
cancer deaths in women in the USA. Approximately 1 in 7 women in the United States will be
diagnosed with breast cancer during her lifetime (Jemal et al., 2004). Over 210,000 new cases
of breast cancer are diagnosed in the United States each year (Centers for Disease Control and
Prevention, 2006). Breast cancer is the cause of death of over 40,000 women in the United
States each year. Many drugs have been demonstrated to extend survival of breast cancer
patients. Anticancer agents frequently used to treat breast cancer include chemotherapeutic
drugs such as methotrexate, 5-fluorouracil (5-FU), cyclophosphamide, anthracyclines, taxanes,
monoclonal antibodies such as trastuzumab, hormonal based therapeutics such as tamoxifen
and aromatase inhibitors. Mechanisms by which these agents inhibit breast cancer progression
vary from drug to drug. While these drugs are the mainstay of chemo, immuno and hormonal
therapy of breast cancer, a common problem with these treatments is the development of drug
resistance. Breast cancer cells can become drug resistant by multiple mechanisms which
include: increased expression of membrane transporters which transport the toxic drug out of
the cell or modify/detoxify the drug, increased expression of signaling and anti-apoptotic
pathways as well as other mechanisms which allow the cells to grow in the presence of the
drug. This manuscript will discuss some of the mechanisms by which the altered expression
of key signaling and apoptotic pathways may lead to breast cancer drug resistance and how
targeting these pathways may result in the suppression of neoplastic growth.
Overview of the PI3K/PTEN/Akt/mTOR and Raf/MEK/ERK pathways and their roles in breast
cancer
Mutations may occur in breast and other cancer cells which result in elevated expression or
constitutive activation of various growth factor receptors such as the epidermal growth factor
receptor (EGFR or c-Erb-B1) or the related c-Erb-B2 receptor. The PI3K/PTEN/Akt/mTOR
and Raf/MEK/ERK pathways are often activated by mutations/amplifications in these and
other growth factor receptors. These pathways are also regulated by upstream Ras which is
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mutated in 20 to 30% of human cancers. The PI3K and B-Raf kinases are also activated by
mutation and in particular in breast cancer (Hollestelle et al., 2007). Many of the events elicited
by the PI3K/PTEN/Akt/mTOR and Raf/MEK/ERK pathways have direct effects on survival
and proliferative pathways. Aberrant regulation of these pathways can contribute to
uncontrolled cell growth and lead to malignant transformation. Effective targeting of these
pathways may result in suppression of cell growth and death of malignant cells. An overview
of the effects of PI3K/PTEN/Akt/mTOR and Raf/MEK/ERK pathways on downstream
signaling pathways leading to growth and the prevention of apoptosis in breast cancer is
presented in Figure 1.
The PI3K/PTEN/Akt/mTOR and Raf/MEK/ERK pathways are also activated by many growth
factors and cytokines which are important in driving proliferation and preventing apoptosis of
breast cells (Blalock et al., 1999, Lee et al., 2002, Steelman et al., 2004, McCubrey et al.,
2005, McCubrey et al., 2007). After growth receptor ligation, Shc, a Src homology (SH)-2
(SH2)-domain containing protein, becomes associated with the c-terminus of the growth factor
receptor (Matsuguchi et al., 1994, Inhorn et al., 1995, Okuda et al., 1999). Shc recruits the
GTP-exchange complex growth factor receptor bound-2 (Grb2)/son of sevenless exchange
(Sos) proteins resulting in the loading of membrane bound Ras with GTP (Tauchi et al.,
1994, Lanfrancone et al., 1995). Ras:GTP then recruits Raf to the membrane where it becomes
activated, likely via a Src-family tyrosine (Y) kinase (Karin et al., 1994, Lange-Carter et al.,
1994, Marais et al., 1995). Raf is responsible for phosphorylation of the mitogen associated/
extracellular regulated kinase-1 (MEK1) (Xu et al., 1995, Marais et al., 1997, Mason et al.,
1999). MEK1 phosphorylates extracellular regulated kinases 1 and 2 (ERKs 1 and 2) on specific
threonine (T) and Y residues (Xu et al., 1995, Marais et al., 1997, Mason et al., 1999). Activated
ERK1 and ERK2 serine (S)/T kinases phosphorylate and activate a variety of substrates. The
number of potential substrates of the ERK kinases has been speculated to be more than several
hundred. The 90 kDa ribosomal six kinase 1 p90Rsk1 is one such substrate (Deng et al.,
1994, Davis et al., 1995, Xing et al., 1996, Cardone et al., 1998, Coutant et al., 2002, Iijima
et al., 2002, Allan et al., 2003, Blalock et al., 2003). p90Rsk1 can activate the cyclic-AMP
response element binding protein (CREB) transcription factor (Xing et al., 1996). Moreover,
ERK can translocate to the nucleus and phosphorylate additional transcription factors such as
Elk1, CREB and Fos which bind promoters of many genes, including growth factor and
cytokine genes important in stimulating the growth and survival of multiple cell types including
breast cells (Deng et al., 1994, Wang et al., 1994, Davis., 1995, Thomas et al., 1997, Robinson
et al., 1998, McCubrey et al., 2000, Aplin et al., 2001, Tresini et al., 2001, Eblen et al.,
2001, Adachi et al., 2002, Ponti et al., 2002, Fry et al., 2002). The Raf/MEK/ERK pathway
can also modulate the activity of many proteins involved in apoptosis including: Bcl-2, Bad,
Bim, myeloid cell leukemia-1 (Mcl-1), caspase 9, and survivin (Deng et al., 2001, Carter et
al., 2003, Jia et al., 2003, Troppmair et al., 2003, Ley et al., 2003, Weston et al., 2003, Domina
et al., 2004, Harada et al., 2004, Marani et al., 2004, Gelinas et al., 2006, McCubrey et al.,
2007).
Growth factor/cytokine receptor ligation also leads to rapid activation of phosphatidylinositol
3-kinase (PI3K) (Martelli et al., 2007). Class IA PI3Ks are heterodimeric proteins which consist
of 85-kDa regulatory and 110-kDa catalytic subunits. The p85 regulatory subunit contains: a
SH2 domain, that recognizes phosphorylated (p) Y (pY) residues, an iSH2 domain (a rigid
tether for p110), a conserved domain related to sequences present in the Break Point Cluster
Region (BCR) gene and a SH3 domain which are found in proteins that interact with other
proteins and mediate assembly of specific protein complexes via binding to proline-rich motifs
(Yu et al., 1996, Fu et al., 2004). The 110-kDa PI3K Cass 1A catalytic subunit contains a p85
binding domain, a Ras binding domain, a kinase domain and a helical domain (Chang et al.,
2003, Steelman et al., 2004). Cytokine stimulation often creates a PI3K binding site on the
cytokine receptor. The p85 subunit SH2 domain associates with this site (Rao et al., 1995,
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Drexler et al., 1996, Chang et al., 2003). The p85 subunit is then phosphorylated which leads
to activation of the p110 catalytic subunit. This often occurs at the inner leaflet of the
cytoplasmic membrane, although there are important roles of PI3K in the nuclear membranes
which have been reviewed recently (Martelli et al., 2006, Evangelisti et al., 2007, Cocco et
al., 2007).
The class IA regulatory subunits recruit the p110 catalytic subunit to pY residues in receptors,
adaptor proteins and other molecules. This localizes the class IA p110 subunits in the
membranes where their lipid substrates reside. The adaptor/regulatory subunits act to localize
PI3K to the plasma membrane by the interaction of their SH2 domains with pY residues in
activated receptors. They also serve to stabilize p110 and to limit its activity.
The preferred substrate for class I PI3K, which is the class of PI3K discussed in this manuscript,
in vivo is phosphatidylinositol 4,5 bisphosphate [PtdIns(4,5)P2] which is phosphorylated to
yield phosphatidylinositol 3,4,5 trisphosphate [PtdIns(3,4,5)P3]. PtdIns(3,4,5)P3 serves as an
anchor for pleckstrin homology (PH) domain-containing proteins, such as Akt or
phosphoinositide-dependent protein kinase-1 (PDK-1). PDK1 then phosphorylates an Akt T
regulatory residue. Akt is also a member of a multi-gene family (Akt-1, Akt-2 and Akt-3) and
is also called protein kinase B (PKB). Depending on the Akt isoform, PDK1 can phosphorylate
Akt on T 308/309/305. A second kinase phosphorylates Akt on a S regulatory residue (S
473/474/472) (Songyang et al., 1997, Troussasrd et al., 2003, Xu et al., 2003, Persad et al.,
2003). The identity of the second kinase which phosphorylates Akt has remained elusive.
Integrin linked kinase (ILK), PDK1, rictor-mTOR complex (see below) and Akt
autophosphorylation have all been suggested to be responsible for phosphorylation of Akt at
the second S phosphorylation site (Noguchi et al., 2007). The PH domain leucine-rich repeat
protein phosphatase (PHLPP) dephosphorylates S473 on Akt which induces apoptosis and
inhibits tumor growth (Gao et al., 2005)
Akt has been postulated to phosphorylate over nine thousand proteins (Lawlor et al., 2001,
Hay, 2005). Thus Akt is clearly a critical growth regulatory switch. Akt can transduce an anti-
apoptotic signal by phosphorylating downstream target proteins involved in the regulation of
cell growth [e.g., glycogen synthase kinase-3β (GSK-3β), apoptotic signal kinase (ASK1),
Bim, Bad, MDM-2, p21Cip1, X-linked inhibitor of apoptosis (XIAP) and the Foxo3a
transcription factor] (Songyang et al., 1997, del Peso et al., 1997, Scheid et al., 1998, Nakae
et al., 1999, Brunet et al., 1999, Mayo et al., 2000, Medema et al., 2000, Dijkers et al., 2000,
Mayo et al., 2001, Gottlieb et al., 2002, Zhou et al., 2002, Dan et al., 2004, Qi et al., 2006).
Phosphorylated Foxo3a loses its ability to induce Fas, p27Kip1, Bim, Noxa, and Puma gene
transcription (You et al., 2006, Obexer et al., 2007). Akt also phosphorylates I-κB kinase (I-
κK), which subsequently phosphorylates inhibitory subunit (I-κB) which binds nuclear
transcription factor kappa light chain in B cells (NF-κB) transcription factor, resulting in its
ubiquitination and subsequent degradation in proteosomes (Ozes et al., 1999, Romashkova et
al., 1999, Mayo et al., 2000, Madrid et al., 2000, Howe et al., 2002, Howe et al., 2004, Hu et
al., 2004, Shishodia et al., 2004). Disassociation of I-κB from NF-κB enables NF-κB to
translocate into the nucleus to promote gene expression. The PI3K/Akt pathway can also
phosphorylate and activate CREB which regulates transcription of Mcl-1 and B cell
leukemia-2 Bcl-2 (Du et al., 1998, Wang et al., 1999, Arcinas et al., 2001). The PI3K/Akt
pathway also regulates the mammalian target of rapamycin (mTOR) and ribosomal protein
kinases such as p70 ribosomal six kinase (p70S6K) (Mahalingam et al., 1996, Dufner et al.,
1999, Romanelli et al., 1999, Harada et al., 2001, Edinger et al., 2004, Panwalker et al.,
2004, Jonassen et al., 2004, Ma et al., 2005) (see Below). It is worth noting that Akt can cause
the activation of specific substrates (e.g., IκKα and CREB) or may mediate the inactivation of
other proteins (e.g., Raf-1, B-Raf [by the Akt related kinase serum glucocorticoid kinase
(SGK)], p21Cip-1, Bim, Bad, procaspase-9, Foxo3a, and GSK-3β). An overview of the effects
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of the PI3K/PTEN/Akt/mTOR and Raf/MEK/ERK pathways on apoptotic and cell cycle
cascades is presented in Figure 2.
mTOR is a 289-kDa S/T kinase. It regulates translation in response to nutrients/growth factors
by phosphorylating components of the protein synthesis machinery, including p70S6K and
eukaryotic initiation factor (eIF)-4E binding protein (4EBP-1), the latter resulting in release of
the translation initiation factor eIF-4E, allowing eIF-4E to participate in the assembly of a
translational initiation complex (Wendel et al., 2004). p70S6K, which can also be directly
activated by PDK-1, phosphorylates the 40S ribosomal protein, S6, leading to active translation
of mRNAs (Giles et al., 2005). Integration of a variety of signals (mitogens, growth factors,
hormones) by mTOR assures cell cycle entry only if nutrients and energy are sufficient for cell
duplication (Fingar et al., 2004, Tokunaga et al., 2004). Therefore, mTOR controls multiple
steps involved in protein synthesis, but importantly enhances production of key molecules such
as c-Myc, cyclin D1, p27Kip1, and retinoblastoma protein (pRb) (Martin et al., 2004). mTOR
also controls the translation of hypoxia-inducible transcription factor-1α (HIF-1α) mRNA.
HIF-1α upregulation leads to increased expression of angiogenic factors such as vascular
endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) (Witzig et al.,
2006). Moreover, HIF-1α regulates the glycolytic pathway by controlling the expression of
glucose-sensing molecules including glucose transporter (Glut) 1 and Glut3 (Mobasheri et
al., 2005).
By regulating protein synthesis, p70S6K and 4E-BP1 also control cell growth and hypertrophy,
which are important processes for neoplastic progression. Akt-mediated regulation of mTOR
activity is a complex multi-step phenomenon. Akt inhibits tuberous sclerosis 2 (TSC2 or
hamartin) function through direct phosphorylation (Manning et al., 2002). TSC2 is a GTPase-
activating protein (GAP) that functions in association with the putative tuberous sclerosis 1
(TSC1 or tuberin) to inactivate the small GTPase protein Rheb (Ras homolog enriched in
brain) (Zhang et al., 2003). TSC2 phosphorylation by Akt represses GAP activity of the TSC1/
TSC2 complex, allowing Rheb to accumulate in a GTP-bound state. Rheb-GTP then activates,
through a mechanism not yet elucidated, the protein kinase activity of mTOR when complexed
with the Raptor (Regulatory associated protein of mTOR) adaptor protein and mLST8, a
member of the Lethal-with-Sec-Thirteen gene family, first identified in yeast (Hay, 2005). The
mTOR/Raptor/mLST8 complex (mTORC1) is sensitive to rapamycin and, importantly,
inhibits Akt via a negative feedback loop which involves, at least in part, p70S6K (Hay,
2005). The relationship between Akt and mTOR is further complicated by the existence of the
mTOR/Rictor (Rapamycin-insensitive companion of mTOR/mLST8 complex (mTORC2),
which displays rapamycin-insensitive activity. The mTORC2 complex has been found to
directly phosphorylate Akt on S473 in vitro and to facilitate T308 phosphorylation. Thus, the
mTORC2 complex might be the elusive PDK-2 which phosphorylates Akt on S473 in response
to growth factor stimulation (Hresko et al., 2005). Akt and mTOR are linked to each other via
ill-defined positive and negative regulatory circuits, which restrain their simultaneous
hyperactivation through a mechanism involving p70S6K and PI3K. Assuming that equilibrium
exists between these two complexes within the cell, when the mTORC1 complex is formed, it
could antagonize the formation of the mTORC2 complex and reduce Akt activity (Hresko et
al., 2005). Thus, at least in principle, inhibition of the mTORC1 complex could result in Akt
hyperactivation. This is one complication associated with rapamycin treatment (see below).
The PI3K/PTEN/Akt/mTOR pathway is negatively regulated by phosphatases. PTEN
(phosphatase and tensin homologue deleted on chromosome ten) is primarily a lipid
phosphatase that removes the 3-phosphate from the PI3K lipid product PtdIns (3,4,5)P3 to
produce PtdIns (4,5)P2 which prevents Akt activation (Chang et al., 2003, Li et al., 1997.,
Steck et al., 1997, Li et al., 1997, Steelman et al., 2004, Shaw et al., 2006). PTEN is also a
protein phosphatase (Steelman et al., 2004, Mahimainathan et al., 2004, Raftopoulou et al.,
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2004). Two other phosphatases, SH2 domain-containing inositol 5′phosphatase (SHIP)-1 and
SHIP-2, remove the 5-phosphate from PtdIns(3,4,5)P3 to produce PtdIns(3,4)P2 (Damen et
al., 1996, Kavanaugh et al., 1996, Lioubin et al., 1996, Muraille et al., 1999, Taylor et al.,
2000). Mutations in these phosphatases, which eliminate their activity, can lead to tumor
progression. Consequently, the genes encoding these phosphatases are referred to as anti-
oncogenes or tumor suppressor genes.
Signaling pathways and breast cancer
Breast cancer originates from genetic causes. Mutated or amplified genes are either inherited
or occur sporadically. Hereditary breast cancer accounts for only about 10% of all breast cancer
cases and generally results from lack of a tumor suppressor gene as opposed to gain of an
oncogene. Approximately 45% of hereditary breast cancer is attributable to mutations in breast
cancer associated gene-1 (BRCA1) and an additional 45% is attributable to mutation in BRCA2
(Centers for Disease Control and Prevention, 2006). Other tumor suppressor genes implicated
in hereditary breast cancer include p53 and PTEN (Steelman et al., 2004). The p53 tumor
suppressor is a transcription factor involved in cell cycle regulation and DNA damage repair.
Germline p53 mutation is present in approximately 50% of patients with Li-Fraumeni
syndrome (LFS), which is a multicancer familial syndrome that includes adrenocortical
carcinoma, brain tumors, leukemia, and osteosarcomas in addition to early onset breast cancer.
Breast cancer attributable to germline p53 mutation in the absence of LFS is rare. Germline
PTEN mutation is present in approximately 80% of patients with Cowden syndrome (CS)
(Navolanic et al., 2003, Steelman et al., 2004). This disease, which is also known as multiple
hamartoma syndrome, is another familial syndrome that includes many different types of
cancer conditions including early onset breast cancer. Mutations have been reported to occur
at PTEN in breast cancer in varying frequencies (5-21%) (Rhei et al., 1997, Singh et al.,
1998, Feilotter et al., 1999, DeGraffenried et al., 2004, Hollestelle et al., 2007). Loss of
heterozygosity (LOH) at PTEN is probably more common (30%) (Singh et al., 1998). PTEN
promoter methylation leads to low expression. In one study, 26% of primary breast cancers
had low PTEN levels (Singh et al., 1998). Low PTEN levels have been correlated with lymph
node metastases and poor prognoses (Singh et al., 1998, DeGraffenried et al., 2004, Garcia et
al., 2004, Tsutsui et al., 2005). Mutations at certain residues of PTEN, which are associated
with CS, affect the ubiquitination of PTEN and prevent nuclear translocation. These mutations
leave the phosphatase activity intact (Trotman et al., 2007). Inhibition of PTEN activity leads
to centromere breakage and chromosome instability (Shen et al., 2007). PTEN expression may
also be silenced in the absence of obvious genetic mutations. Disruption of PTEN activity by
various genetic mechanisms could have vast effects on different processes affecting the
sensitivity of breast cancers to diverse therapeutic approaches.
Sporadic breast cancer accounts for the remaining 90% of all breast cancer cases. The PI3K
p110 catalytic subunit is mutated in approximately 25% of breast cancer specimens and these
mutations frequently result in activation of its kinase activity (Bader et al., 2005, Kang et al.,
2005, Engleman et al., 2006, Vogt et al., 2006, Tokunaga et al., 2006, Hollestelle et al.,
2007) (See below). Somatic mutation of p53 is associated with many cancers and exists in
approximately 20% of sporadic breast cancer cases. In contrast, somatic mutation of BCRA1
or BCRA2 is rare in breast cancer patients. Another important cause of sporadic breast cancer
is amplification/overexpression of HER2 which occurs in approximately 25 to 30% of breast
cancer. Expression and activity of downstream signal transduction cascades, such as the PI3K/
PTEN/Akt/mTOR and Raf/MEK/ERK pathways, change as a result of these mutations. Akt
and ERK are frequently activated in breast cancer specimens (Hollestelle et al., 2007,
Greenman et al., 2007). Thus the PI3K/PTEN/Akt/mTOR and Raf/MEK/ERK pathways are
therapeutic targets in breast cancer.
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Association of genes that regulate signal transduction pathways with breast cancer implies an
important role of these pathways in this disease. Perhaps the best example of this is association
of HER2 gene amplification with breast cancer. While a normal breast cell possesses 20,000
to 50,000 HER2 molecules, amplification of this gene can increase levels of HER2 up to
2,000,000 molecules per cell (Chang et al., 2003, Shelton et al., 2005a). Overexpression of
HER2 in breast cancers is linked to comedo forms of ductal carcinoma in situ (DCIS). DCIS
is present in approximately 90% of the patients with HER2 amplification. HER2
overexpression will lead to increased expression of both the Raf/MEK/ERK and PI3K/Akt
pathways. An overview of some of the mutations which can result in activation of the PI3K/
PTEN/Akt/mTOR and Raf/MEK/ERK cascades is presented in Figure 3.
Effective targeting of signal transduction pathways activated by mutations and gene
amplification may be an effective means to limit cancer growth and metastasis (See below).
The PI3K/PTEN/Akt/mTOR and Raf/MEK/ERK and PI3K/Akt pathways can be activated by
mutations/amplifications of upstream growth factor receptors.
Mutations that lead to the expression of constitutively-active Ras proteins have been observed
in approximately 20 to 30% of human cancers (Flotho et al., 1999, Stirewalt et al., 2001). These
are often point mutations which alter key residues that affect Ras activity, although
amplification of Ras is also detected in some tumors. Mutations that result in increased Ras
activity also perturb the PI3K/PTEN/Akt/mTOR and Raf/MEK/ERK kinase cascades.
In a recent survey of 40 breast cancer lines, many were mutated at components of either the
PI3K/PTEN/Akt/mTOR or Raf/MEK/ERK pathways (Hollestelle et al., 2007). 36% were
mutated at PIK3CA (PI3K p110 subunit gene), 21% at PTEN (with PTEN either mutation or
no protein present), 13% were mutated at K-RAS, 5% at H-RAS, 3% at N-RAS, and 10% at B-
RAF. In other studies it has been shown that the PI3K p110 catalytic subunit (PIK3CA) is
mutated in: approximately 25% of breast, 32 % of colorectal, 27% of brain, 25% of gastric,
4% of lung cancers (Samuels et al., 2004; Kang et al., 2005, Vogt et al., 2006). These mutations
frequently result in activation of its kinase activity. A recent report indicated that Akt-1 is
mutated in: 8% of breast, 6% of colorectal and 2% of ovarian cancers examined in that study
(Carpten et al., 2007). This mutation results in a lysine (K) substitution for glutamic acid (E)
at amino acid 17 (E17K) in the PH domain. Cells with this Akt1 mutation have not been
observed to have mutations at PI3K, a similar scenario is also frequently observed with Ras
and B-Raf mutations (Greenman et al., 2007). The Akt mutation alters the electrostatic
interactions of Akt which allows it to form new hydrogen bonds with the natural
phosphoinositol ligand (Carpten et al., 2007). The PH domain mutation confers many different
properties to the Akt-1 gene. Namely, the mutant Akt-1 gene: 1) has an altered PH domain
conformation, 2) is constitutively active, 3) has an altered cellular distribution as it is
constitutively associated with the cell membrane, 4) morphologically transforms Rat-1 tissue
culture cells and 5) interacts with c-Myc to induce leukemia in Eμ-Myc mice (Eμ = enhancer
of immunoglobulin M (μ) gene, Myc = Myc oncogene originally isolated in avian
myelocytomatosis virus) (Carpten et al., 2007). This PH domain mutated Akt-1 gene does not
alter its sensitivity to ATP competitive inhibitors, but does change its sensitivity to allosteric
kinase inhibitors (Carpten et al., 2007). These results demonstrate that targeting the kinase
domain of Akt may not be sufficient to suppress the activity of various Akt genes which have
mutations in the PH domain (Carpten et al., 2007). It will be important to determine if this
Akt-1 mutation (E17K) is also present in other solid and non solid tumors as well as its overall
mutation frequency in human cancer. In summary, mutations do occur at key components of
the PI3K/PTEN/Akt/mTOR and Ras/Raf/MEK/ERK pathways in breast cancer and targeting
of these pathways may be important therapeutic approach, either by themselves as
monotherapy or combination methods with various chemo-hormonal- and antibody treatments.
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Furthermore as stated previously, components of these pathways may be activated either by
upstream mutations or by other genetic/epigenetic mechanisms. Activated Akt is often
upregulated in breast cancer cells and its overexpression has been associated with a poor
prognosis (Clark et al., 2002, DeGraffenried et al., 2004, Tsutui et al., 2005, Kirkegaard et
al., 2005, Tokunaga et al., 2006). However, this may actually render the breast cancer cells
sensitive to Akt as well as downstream mTOR inhibitors. The formation of the rapamycin
sensitive mTORC1 complex in the drug resistant breast cancer cells which overexpress
activated Akt may be different than in drug sensitive breast cells which do not overexpress
activated Akt. In cells which express activated Akt, Akt should phosphorylate TSC-2 resulting
in its inactivation. mTORC1 complex is then formed and downstream p70S6K and 4E-BP1
are phosphorylated, allowing the disassociation of eIF-4E, ribosome biogenesis and protein
synthesis. In contrast, in the absence of constitutive Akt and ERK activation, which is the case
in the drug sensitive cell, this complex should not be formed. Rapamycin targets this complex;
hence the cells which constitutively-express activated Akt cells are more sensitive to rapamycin
than the cells which do not. In the cells which do not constitutively-express activated Akt, this
complex should be transiently assembled after growth factor treatment. In contrast, the
assembly of the rapamycin-insensitive mTORC2 complex (Rictor, mTOR, mLST8) should be
lower in the cells that constitutively express activated Akt than in those cells that do not as
there is equilibrium between the mTORC1 and mTORC2 complexes. The significance of these
complex biochemical signaling events is that breast cancer cells which overexpress activated
Akt or lack PTEN expression have an Achilles heel with regards to therapeutic intervention as
they are highly sensitive to rapamycin treatment. Breast cancer may also be sensitive to Raf/
MEK inhibitors as ERK plays critical roles in the phosphorylation of TSC-2 and p70S6K (see
below).
We have observed that ERK is activated after tamoxifen and doxorubicin treatment of the
MCF-7 breast cancer cell line. Furthermore, drug resistant derivative cell lines have increased
levels of constitutively active ERK. These results are important with regards to the sensitivity
of breast cancer cells to MEK inhibitors. ERK can phosphorylate and contribute to the
inactivation of TSC-2. Akt can also phosphorylate TSC-2, at a different residue, which leads
to its inactivation. This also leads to mTOR activation. Inhibition of TSC-2 phosphorylation
by PI3K/Akt and Raf/MEK inhibitors may make cells more sensitive to chemo-, hormonal-,
and immunotherapies.
Aberrant regulation of apoptosis may contribute to breast cancer and subsequent drug
resistance
Cell death following cytotoxic drug treatment is generally apoptotic as opposed to necrotic.
Many chemotherapeutic drugs induce apoptosis by activating the intrinsic cell death pathway
which involves cytochrome c release and activation of the apoptosome-catalyzed caspase
cascade. During apoptosis, activation of caspase family cysteine proteases occurs. Although
various cytotoxic drugs differ in their mechanisms of action, each ultimately relies upon built
in apoptotic machinery to elicit cell death (Deng et al., 2001, Harada et al., 2001, Navolanic
et al., 2003, Chang et al., 2003, Steelman et al., 2004, Martelli et al., 2007). Caspase family
cysteine proteases are responsible for proteolytic cleavage of cellular proteins carboxyl
terminal to aspartate residues.
In a study involving 46 breast cancer patients, 75% were determined to lack caspase-3 mRNA
transcripts and protein expression (Devarajan et al., 2002). The MCF-7 cell line has a mutation
in caspase-3 and is deficient in certain aspects of apoptosis. In this respect, MCF-7 cells are a
stringent model to investigate breast cancer apoptosis (Liang et al., 2001). Caspase-9 can be
activated in MCF-7 cells which can result in the sequential activation of caspases-7 and -6
(Twiddy et al., 2006). Caspase-7 is activated by the apoptosome complex and forms a XIAP-
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caspase-7 complex. This XIAP-caspase-7 complex is more stable in MCF-7 cells due to the
absence of functional caspase-3. ERK activity maintains XIAP levels; however the mechanism
by which this occurs is unknown. Resistance to chemotherapeutic drugs induced by the Raf/
MEK/ERK pathway may be due in part to prolonged XIAP and caspase 9 expression which
prevents caspase 7 from exerting its effects on apoptosis (Dan et al., 2004, Gardai et al.,
2004). ERK phosphorylates caspase-9, which inhibits its activation. Negative regulation of
caspases by ERK represents a mechanism by which Raf/MEK/ERK pathway activation
prevents apoptosis. Raf/MEK inhibitors may affect caspase 9 activation and XIAP levels and
promote apoptosis of breast cancer cells (see below).
Therapeutic targeting of the PI3K/Akt/PTEN/mTOR and Raf/MEK/ERK pathways
Small molecule inhibitors such as Imatinib have proven effective in the treatment of chronic
myeloid leukemia (CML) and certain other cancers which proliferate in response to
translocated BCR-ABL, mutant platelet derived growth factor receptor (PDGF-R) and c-Kit
genes (Lee et al., 2002, Hochhaus et al., 2002, Navolanic et al., 2003, Steelman et al., 2004,
Barnes et al., 2005, Hollestelle et al., 2007) such as gastro-intestinal stromal tumors (GIST).
Non small cell lung carcinomas (NSCLC) which have mutations in EGFR are sensitive to
EGFR inhibitors (Lynch et al., 2004, Sordella et al., 2004, Pao et al., 2004, Shelton et al.,
2005, Pao et al., 2005, Sequist et al., 2005, McCubrey et al., 2007). Currently, these cancers
are the poster children of targeted therapies as their growth can be successfully inhibited and
dramatic effects observed in cancer patients. Certain antibodies have been developed such as
Herceptin which effectively target HER2 those breast cancer patients (25 to 30%) which
overexpress HER2 due to genetic amplification and other mechanisms (Shelton et al.,
2005a).
PI3K, PDK, Akt, and mTOR inhibitors have been and are being developed. mTOR inhibitors
have been used for many years as immunosuppressive drugs in kidney transplant patients. A
side effect of mTOR inhibitors is the inhibition of a negative feed back pathway which can
result in Akt activation (Weber et al., 2004). A diagram illustrating the sites of action and other
inhibitors is presented in Figure 4.
PI3K can be inhibited with many inhibitors including: LY294002, Wortmannin, KN309,
SF1124 and PX-866. Novel PI3K inhibitors have been developed. PWT-458 is a pegylated-17-
hydroxywortmannin which inhibits PI3K and has been shown to suppress glioma, NSCLC and
renal cell carcinoma in xenograft models (Yu et al., 2005). PWT-458 augmented the anticancer
effects of paclitaxel and pegylated rapamycin in certain xenograft models.
PDK1 can be inhibited with OSU-03012 and Celecoxib. Akt can be inhibited with many
inhibitors including; A-443654, API-2, PX316, Curcumin, Rotenone (Deguelin), and
Perifosine. Perifosine is an oral bioactive novel alkylphospholipid that inhibits Akt. mTOR
can be inhibited by rapamycin and modified rapamycins (CCI-779, RAD001 and AP23573).
Initially mTOR inhibitors showed much promise as PTEN is often deleted, mutated or silenced
in various tumors by many different mechanisms. However, it has been recently determined
that the mTOR pathway has a complicated feed-back loop which actually involves suppression
of Akt, hence mTOR inhibitors would be predicted to activate Akt in some cells. Due to the
complicated Akt/mTOR pathway, with many inhibitory phosphorylation events, an alternative
therapeutic approach will be to develop strategies which simultaneously inhibit both Akt and
mTOR activity. As pointed out previously, recently mutations in the PH domain of Akt have
been detected in certain human cancers. Cells harboring these mutations may be refractory to
Akt inhibitors which target the kinase domain but may be more sensitive to inhibitors which
target the PH domain (Carpten et al., 2007). The role of overexpression of the different Akt
isoforms in cancer prognosis is controversial (Kornblau et al., 2006, Tamburini et al., 2007).
Some studies have suggested that elevated Akt expression is associated with a poor prognosis
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in breast (Kirkegaard et al., 2005) and hematopoietic (Kornblau et al., 2006) cancers.
Controversially it has been observed recently that constitutive PI3K/Akt activation is a
favorable prognostic factor in AML patients (Tamburini et al., 2007) as Akt activation may
keep a high percentage of the cells in S phase which renders them sensitive to chemotherapeutic
drugs. These and other studies document the complexity of enhanced Akt expression which
may make certain cells more sensitive or resistant to certain anti-cancer therapies.
Recent evidence has highlighted that mTOR can also be activated by Raf/MEK/ERK
(Mukherjee et al., 2005, Shimada et al., 2006). This may well be another relevant cross-talk
between the PI3K/PTEN/Akt/mTOR and Ras/Raf/MEK/ERK pathways and offer a further
rationale for treatments combining drugs which inhibit both signaling networks.
Raf and MEK inhibitors have been developed and some are in clinical trials (Hochhaus et
al., 2002, Navolanic et al., 2003, Steelman et al., 2004, Hollestelle et al., 2007, Tortora et
al., 2007). We have determined that a consequence of doxorubicin and hormonal treatment of
some breast, hematopoietic and prostate cancer cell lines is the induction of ERK (McCubrey
et al., 2007). Eliminating this deleterious side-effect of these compounds with Raf and MEK
inhibitors may enhance the ability of chemo- and hormonal based therapies to kill drug resistant
cancer.
Certain Raf inhibitors have been developed which are small molecule competitive inhibitors
of the ATP-binding site of Raf protein. These inhibitors (e.g., L-779,450, ZM 336372, Bay
43-9006, a.k.a Sorafenib) bind the Raf kinase domain and therefore prevent its activity. Some
Raf inhibitors may affect a single Raf isoform (e.g., Raf-1), others may affect Raf proteins,
which are more similar (Raf-1 and A-Raf), while other pan Raf inhibitors may affect all three
Raf proteins (Raf-1, A-Raf and B-Raf). We have observed that the L-779,450 inhibitor
suppresses the effects of A-Raf and Raf-1 more than the effects of B-Raf (Shelton et al.,
2003). Like many Raf inhibitors, L-779,450 is not specific for Raf; it also inhibits the closely
related p38MAPK. Likewise, Sorafenib inhibits other kinases besides Raf (e.g., VEGF-II
Receptor, PDGF-R, Kit, Flt-3, and Fms) and is more appropriately referred to as a multi-kinase
inhibitor. Knowledge of the particular Raf gene mutated or overexpressed in certain tumors
may provide critical information regarding how to treat the patient as some cancers which
overexpress a particular Raf gene may be more sensitive to inhibition by agents which target
that particular Raf protein. Inhibition of certain Raf proteins might prove beneficial while
suppression of other Raf proteins under certain circumstances might prove detrimental. Thus
the development of unique and broad-spectrum Raf inhibitors may prove useful in cancer
therapy. Some “Raf” inhibitors (Sorafenib) are approved for the treatment of certain cancers
(e.g., renal cell carcinoma) (Heimbrook et al., 1998, Hall-Jackson et al., 1999, Lyons et al.,
2001, Blagosklonny 2002, Shelton et al., 2003, Tortora et al., 2007).
Currently it is believed that MEK1 is not frequently mutated in human cancer. Recently, there
was a report that MEK1 and MEK2, as well as B-Raf, are mutated in some patients with cardio-
facio cutaneous syndrome (Rodriguez-Viciana et al., 2006). Aberrant expression of MEK1 is
observed in many different cancers due to the activation of the Raf/MEK/ERK pathway by
upstream kinases (e.g., BCR-ABL) and growth factor receptors (e.g., EGFR, Fms, Flt-3,
PDGFR) as well as other unknown mechanisms. Specific inhibitors to MEK have been
developed (PD98059, U0126, PD184352 (a.k.a., CI1040), PD-0325901, Array MEK inhibitors
[ARRY-142886 and others]) (Tortora et al., 2007). The successful development of MEK
inhibitors may be due to the relatively few phosphorylation sites on MEK involved in
activation/inactivation. MEK inhibitors differ from most other kinase inhibitors as they do not
compete with ATP binding which confers a very high specificity (Delaney et al., 2002). MEK
inhibitors are very specific and do not inhibit many different protein kinases including
p38MAPK and JNK (Davies et al., 2000). The crystal structures of MEK1 and MEK2 have been
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determined as ternary complexes with ATP and PD184352 and have revealed that both MEK1
and MEK2 have unique inhibitor binding sites located on a hydrophobic pocket adjacent to
but not overlapping with the ATP binding site (Ohren et al., 2004). Furthermore, effective
targeting of MEK1,2 is highly specific as ERK1,2 are the only well-described downstream
targets. An advantage of targeting the Raf/MEK/ERK cascade is that it can be targeted without
knowledge of the precise genetic mutation, which results in its aberrant activation. This is
important as the nature of the critical mutation(s), which leads to the drug resistant growth of
at many breast cancers, is not currently known. An advantage of targeting MEK is that the Raf/
MEK/ERK pathway is a convergence point where a number of upstream signaling pathways
can be blocked with the inhibition of a single kinase (MEK). MEK inhibitors such as
ARRY-142886 (AZD6244) are also being evaluated to treat hematopoietic malignancies such
as multiple myeloma (Tai et al., 2006, Wang et al., 2006, Yeh et al., 2007).
To our knowledge, no small molecular weight ERK inhibitors have been developed yet,
however, inhibitors to ERK could prove very useful as ERK can phosphorylate many targets
(Rsk, c-Myc, Elk, and at least 150 more). There are at least 2 ERK molecules regulated by the
Raf/MEK/ERK cascade, ERK1 and ERK2. Little is known about the different in vivo targets
of ERK1 and ERK2. However ERK2 has been postulated to have pro-proliferative effects while
ERK1 may have anti-proliferative effects (Mazzucchelli et al., 2002). Development of specific
inhibitors to ERK1 and ERK2 might eventually prove useful in the treatment of certain
diseases.
Combination therapies to enhance toxicity and effectiveness of breast cancer therapy
Classical chemotherapy often remains the most used anti-cancer therapy for many different
types of cancers including breast cancer. Drugs such as doxorubicin and taxol are effective in
the treatment of many cancers, even though in some cases drug resistance does develop after
prolonged treatment. Doxorubicin and taxol target cellular events such as DNA replication and
cell division which are downstream of the targets of signal transduction pathway inhibitors.
Thus by combining classical chemotherapy with targeted therapy, it may be possible to enhance
toxicity while lowering the effective concentrations of classical chemotherapeutics necessary
for effective elimination of the particular tumor.
Recent studies have indicated that the effectiveness of certain antibody based therapies (e.g.,
Herceptin, which targets HER2) may be greatly enhanced by inclusion of mTOR inhibitors.
These observations were obtained in both preclinical studies performed in tissue culture and
xenograft models and are being further evaluated in phase 2 clinical trials (Wang et al.,
2007). The cytotoxic effects of Herceptin can also be improved by addition of an inhibitor such
as Lapatinib which targets both EGFR and HER2 (Konecny et al., 2006). Many ongoing
clinical trials are examining the effectiveness of targeting the PI3K/Akt/mTOR and other
pathways. These and the other studies we have described document the promise of targeting
the PI3K/PTEN/Akt/mTOR pathway in human health care. Furthermore, combining classical
chemo and hormonal therapy with PI3K, Akt and mTOR inhibitors is also a very attractive
therapeutic option under intense investigation.
We have investigated the effects of combining classical chemo- or hormonal therapies with
signal transduction inhibitors in suppressing the growth of breast cancer cells. Treatment of
breast cancer cells with MEK or mTOR inhibitors with doxorubicin, paclitaxel or tamoxifen
resulted in a synergistic response documenting the effectiveness of classical chemo- hormonal
with targeted therapies (see below).
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Materials & Methods
Cell Culture
MCF-7 cells were derived from a human breast adenocarcinoma (Soule et al., 1973). MCF-7
cells have an epithelial morphology, are adherent, and form a monolayer in culture. These cells
express both estrogen receptor (ER)α and ERβ (Brooks et al., 1973, Enmark et al, 1997, Fuqua
et al., 1999, Leygue et al., 1999, Fasco et al., 2000, Poola et al., 2000, Yoshida et al., 2000,
Lespagnard et al., 2001, Poola et al., 2002) and (WT) PTEN (Li et al., 1998, Lu et al., 1999,
Weng et al., 1999, Clark et al., 2002). MCF-7 cells were obtained from the American Type
Culture Collection (ATCC) (Manassas, VA).
Cell culture medium for MCF-7 cells consisted of 10% (v/v) heat inactivated fetal bovine
serum (FBS) (CellGrow-Mediatech, Herndon, VA), 2 mM L-glutamine (Invitrogen, Carlsbad,
CA), 100 µg/ml streptomycin (Invitrogen), and 100 units/L penicillin G (Invitrogen) in Roswell
Park Memorial Institute-1640 (RPMI 1640) medium (Invitrogen).
PTEN(WT), PTEN(C124S), and PTEN(G129E)Plasmids
A plasmid encoding human WT PTEN [PTEN(WT)] was generated by inserting the
corresponding cDNA into the multiple cloning site of pEGFP-C2 (Leslie et al., 2000). Mutated
PTEN cDNAs were inserted into the multiple cloning site of pEGFP-C2 to generate plasmids
encoding various PTEN mutants (Leslie et al., 2000). These PTEN mutants include: PTEN
(C124S) and PTEN(G129E). PTEN(C124S) and PTEN(G129E) each differ from PTEN(WT)
by substitution of a single amino acid. PTEN(C124S) lacks both lipid and protein phosphatase
activities (Myers et al., 1997, Leslie et al., 2000). PTEN(G129E) lacks lipid phosphatase
activity yet retains protein phosphatase activity (Leslie et al., 2000). These PTEN mutants were
originally described in CS breast cancer patients and postulated to function as dominant
negative (DN) mutations (Liaw et al., 1997, Weng et al., 2001).
Transfection of MCF-7 cells with PTEN Constructs
5 × 105 MCF-7 cells were plated into 6-well cell culture plates (BD Biosciences,
Mountainview, CA) one day prior to transfection. Cells were rinsed with Opti-MEM medium
(Invitrogen) to remove FBS. Cells were transfected with 10 µg of DNA with Lipofectin
(Invitrogen) as described by the manufacturer. 48 hrs after transfection, selection medium
(RPMI + 10% FBS + 2 mg/ml G418) (Geneticin, Invitrogen, Carlsbad, CA) was added to
isolate stably transfected cells. Cells were provided with fresh selection medium every three
days. Mock transfections were performed by replacing DNA with 10 µl of Tris-EDTA buffer.
Mock transfected MCF-7 cells did not generate viable colonies in the presence of selection
medium. The number of MCF-7 colonies present after incubation in selection medium for 3
weeks was determined. The mean number of MCF-7 colonies present and corresponding
standard deviation was calculated from 3 replicate wells for each plasmid. The transfections
were repeated 4 times and averaged together.
Analysis of Sensitivity to Doxorubicin and Rapamycin
Cells were seeded in 96-well cell culture plates (BD Biosciences) at a density of 5,000 cells/
well in 100 µl/well of phenol red free RPMI-1640 containing 5% charcoal stripped FBS (CS-
FBS). Cell culture plates were incubated for 1 day to permit cells to adhere to the bottom of
each well. A 100 µl dose of treatment medium (doxorubicin or rapamycin) was added to each
well the day after cells were initially seeded. Cell culture plates were incubated at 37 °C until
extent of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT, Sigma,
St. Louis, MO) reduction in each well was quantified. Absorbance of each well was measured
at 530 nm with a FL600 microplate fluorescence reader (Bio-Tek Instruments, Winooski, VT).
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The mean and corresponding standard deviation of normalized adjusted absorbance was
calculated from 8 replicate wells for each drug concentration and duration of incubation in
order to investigate effects of the drug and ectopic gene expression on cell proliferation rate.
Inhibitory concentration 50% (IC50) is defined in this context as the concentration of the drug
that causes MCF-7 cells to proliferate at a rate that is half as rapid as cells incubated in the
absence of the drug.
Apoptosis Analysis
The extent of apoptosis in the PTEN transfected cells after exposure to different concentrations
of doxorubicin was estimated by determining the percentage of sub-G1 cells by flow cytometric
analysis after PI staining of the cells. Results were analyzed by the ModFit LT 3.1 software
program (Verity Software, Topsham, ME).
Clonogenic Assays
MCF-7 cells were collected and seeded in 6-well cell culture plates at densities of 1000 and
2000 cells/well (3 wells at each density). Cell culture plates were incubated for 1 day at 37 °
C in a cell culture incubator to permit cells to adhere to the bottom of each well. Cell culture
plates were incubated for 3-4 weeks at 37 °C in a cell culture incubator. Cells were provided
with fresh treatment containing 100 nM doxorubicin, 100 nM 4-hydroxy tamoxifen (4HT,
Sigma), the combination of doxorubicin and 4HT or no supplement every 3 days. Cells were
rinsed with PBS at the end of the 3 week treatment period. Rinsed cells were fixed in 100%
(v/v) methanol (Sigma) for 10 minutes at room temperature then dried for 10 minutes at room
temperature. Fixed cells were incubated in Giemsa stain (Sigma) for 5 minutes at room
temperature. Stained cells were rinsed with water then dried. The number of colonies present
in each well was counted. Colonies consisted of at least 50 cells. The mean number of colonies
and corresponding standard deviation was calculated from 3 replicate wells for each condition.
Cellular Senescence Assay
When cells undergo senescence, they express senescence associated (SA) β-galactosidase (SA-
β-gal). Senescent cells can be stained by a SA-β-gal senescence assay. 25,000 cells were seeded
in each well of a 6 well plate containing an etched cover slip at different concentrations of
doxorubicin and incubated for 4 days. SA-β-gal hydrolyzes X-gal (5-bromo-4-chloro-3-indolyl
b-D-galactopyranoside) into a colorless galactose and 4-chloro-3-brom-indigo which forms an
intense blue precipitate. SA-β-gal activity was detected at pH 6.0 as lysosomal β-gal has a pH
optimum of 4.0. Senescent cells contained a dark blue stain in the perinuclear area, and
displayed altered morphology. Fixed cells were photographed with a Nikon Eclipse E600
microscope under bright field settings.
Western blot analysis
MCF/EGFPc2 and MCF/PTEN(G129E) cells were collected after trypsination and plated in
100 mm tissue culture plates and cultured in RPMI + 10% FBS. After allowing the cells to
adhere for 24 hrs, the monolayers were washed twice with PBS and then cultured with phenol
red free RPMI 1640 containing 0.5% CS-FBS (to avoid endogenous estrogenic like compounds
and reduce serum growth factors) for 24 hrs. Cells were then stimulated with 10% FBS for the
indicated time intervals and protein lysates prepared as previously described (Shelton et al.,
2005b). Western blots were performed with antibodies specific for phospho and total Akt,
Ask-1, p70S6K, ERK and Hsp70, as previous described (Shelton et al., 2005b). Antibodies
used in this study were purchased from Cell Signaling (Beverly, MA).
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Results and discussion
Increased PTEN expression suppresses colony formation of MCF-7 cells
MCF-7 cells were transfected with PTEN plasmids encoding WT, C124S, G129E or the empty
vector EGFP-C2 (Leslie et al., 2000) to determine how signals transduced by this pathway
affect breast cancer cell proliferation. The number of colonies present after transfection with
plasmids encoding the PTEN mutants C124S or G129E or the empty vector EGFP-C2 were
not statistically different. However, a decrease in the number of colonies was observed after
transfection with a WT PTEN plasmid in comparison to transfection with the other plasmids.
Thus increased expression of WT PTEN decreased the number of colonies isolated directly
after selection in medium containing G418.
Effects of PTEN mutants on growth and induction of apoptosis in the presence of
doxorubicin
The proliferation of pools of MCF-7 cells stably transfected with WT, C124S, G129E PTEN
genes was compared with empty vector EGFP-C2 transfected cells, in the presence of different
concentrations of doxorubicin over a 4 day time period in 96 well plates at 5000 cells/well.
The growth of PTEN WT and EGFP-C2 transfected cells were similar in medium containing
0, 125 and 500 nM doxorubicin and no growth was observed at 2000 nM doxorubicin. Thus
in stably transduced pools of PTEN (WT) and empty vector transfected cells, which had been
isolated and expanded in culture for over one month, there was no difference in growth rates
while there were differences in the initial colony formation efficiencies. In contrast, the growth
PTEN mutant C124S and G129E cells differed from EGFP-C2 cells both in the absence and
presence of doxorubicin. In the absence of doxorubicin, the mutant PTEN transfected cells
reached lower saturation densities and proliferated at slower rates, while at higher doxorubicin
concentrations, the mutant PTEN transfected cells proliferated to higher levels than either the
EGFP-C2 or WT PTEN transfected cells. Thus, altering the levels of the PTEN mutant
phosphatases changed the growth properties of MCF-7 cells both in the presence and absence
of doxorubicin, but did not affect the colony formation efficiencies in the absence of
doxorubicin.
The effects of the mutant and WT PTEN genes on the doxorubicin IC50s were determined.
While the IC50S for the PTEN WT and empty vector transfected cells in the presence of
doxorubicin were similar, the mutant PTEN transfected cells had higher IC50s for doxorubicin.
The IC50s for doxorubicin in the C124S and G129E mutant PTEN transfected cells were 8.6
and 6.2-fold higher than empty vector or PTEN WT transfected cells. Statistical analysis
revealed that the IC50 in the lipid and protein phosphatase deficient PTEN mutant transfected
cells (C124S) was higher than in the PTEN mutant (G129E) transfected cells which just lacked
PTEN phosphatase activity.
The effects of the PTEN mutants on the suppression of apoptosis were determined. MCF-7
cells transfected with WT PTEN, the various PTEN mutants or the empty EGFP-c2 vector
were treated with different concentrations of doxorubicin and the extent of apoptosis measured
by determining the percentage of sub-G1 cells after PI staining followed by flow cytometric
analysis. Less apoptotic cells were observed in MCF-7 cells transfected with the PTEN mutants
than in the PTEN WT or empty vector transfected cells. Furthermore less apoptotic cells were
recovered from the MCF-7 cells transfected with the PTEN mutant lacking the lipid and protein
phosphatase activity than the mutant lacking just lipid phosphatase activity. Thus altering the
PTEN phosphatase activity decreased the induction of apoptosis by doxorubicin.
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Mutant PTEN genes alter colony formation in medium containing doxorubicin or tamoxifen
The effects of inheritance of WT and mutant PTEN genes on colony formation in the presence
and absence of chemotherapeutic (doxorubicin) and hormonal (tamoxifen [4HT]) based drugs
were examined. The PTEN mutants had a higher cloning efficiency in medium containing 4HT
than the PTEN (WT) or EGFP-C2 transfected cells. The lipid and protein phosphatase deficient
mutant had a higher cloning efficiency in the presence of doxorubicin than the empty vector
transfected cells. Thus the mutant PTEN gene altered the colony forming ability in the presence
of drugs used to treat cancer patients.
Induction of cellular senescence in breast cancer cells after doxorubicin treatment
When certain cells are treated with chemotherapeutic drugs, they undergo cellular senescence.
Drug resistance is often associated with an inhibition of cellular senescence (Ellmore et al.,
2005, Lehmann et al., 2007). When cells undergo senescence, they express SA-β-gal.
Senescent cells can be visualized by a SA-β-gal senescence assay.
In the absence of doxorubicin, very little senescence was observed after a four day incubation
period in the different PTEN transfected cells. In contrast in the MCF-7 cells transfected with
the PTEN mutations resulting in loss of lipid or lipid and protein phosphatase activity, increased
resistance to chemotherapeutic drug induced cellular senescence was observed. The C124S
mutation deactivates both the lipid and protein phosphatase activity of PTEN, and conferred
the strongest resistance to drug induced senescence. The G129E mutation disengaged only the
lipid phosphatase activity, and also bestowed drug resistance, but still yielded more senescent
cells upon doxorubicin treatment than the C124S mutation. Senescent cells flattened out and
assumed a much wider shape in a 2-D plane. Photographs documenting the difference in the
induction of cellular senescence in the empty vector and PTEN mutant C124S transfected cells
after doxorubicin treatment are presented in Figure 5. In summary, both the protein
phosphatase, as well as the lipid phosphatase activities of PTEN were important with regards
to chemosensitivity in terms of both colony formation and inhibition of cellular senescence.
Effects of mutant PTEN expression on downstream signal transduction pathways important
in breast cancer
The effects of inheritance of phosphatase deficient PTEN genes on signal transduction
pathways were determined. Akt activation was monitored as decreased PTEN expression could
result in Akt activation. Apoptotic signal kinase-1 (Ask-1) phosphorylation was also examined
as it lies downstream of Akt. Phosphorylation of Ask-1 results in its ubiquitination and
subsequent proteosomal degradation. p70S6K phosphorylation was monitored as it lies
downstream of mTOR, is an important regulator of protein synthesis and its activation is a
reflection of functional activation of this pathway. Activation of ERK was also examined as it
is an important kinase implicated in proliferation and prevention of apoptosis and its activity
can be regulated by Akt.
Upon serum stimulation of EGFP-C2 transfected cells, activated Akt was detected after one
hr, however, its levels then decreased at later time points up to 24 hrs. In contrast, the levels
of total Akt protein remained constant. Thus serum treatment, led to a transient increase in
phosphorylated Akt. In contrast, activated Akt was detected after one hr of stimulation of
mutant PTEN transfected cells and remained elevated throughout the time course. Thus the
mutant PTEN transfected cells expressed activated Akt for prolonged time periods after serum
treatment.
Higher levels of phosphorylated Ask-1 were detected in the mutant PTEN transfected than in
empty vector transfected cells. Phosphorylated and ubiquitinated Ask-1 may contribute to the
apoptotic resistance of the mutant PTEN transfected cells.
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The levels of phosphorylated p70S6K increased in empty vector transfected cells 8 and 24 hrs
after serum addition. Phosphorylated p70S6K was detected with phosphospecific antibodies
which detect phosphorylation of p70S6K at either T389 or T421 and S424. In contrast,
relatively equal levels of total p70S6K were detected. The levels of phosphorylated p70S6K
were low after serum deprivation of mutant PTEN transfected cells but increased rapidly after
serum addition (0.5 hr) and remained elevated over the time course. Thus the mutant PTEN
transfected cells expressed activated p70S6K earlier than the empty vector transfected cells.
Phosphorylated ERK was detected 4 hrs after FBS stimulation of empty vector transfected cells
and remained elevated for 24 hrs. In contrast, activated ERK was detected constitutively in the
mutant PTEN transfected cells. Thus disruption of PTEN activity results in alterations in Akt,
Ask-1, p70S6K and ERK activation. These results document the dramatic effects that altered
PTEN expression can have on downstream anti-apoptotic and growth related signaling
Mutant PTEN genes confer an Achilles' heel to drug resistant breast cancer cells
It has been reported that altering Akt or PTEN levels will change the sensitivity of breast cancer
cells to rapamycin (DeGraffenried et al., 2004). However, the relationships between PTEN,
rapamycin and chemotherapeutic drug resistance in breast cancer are not clearly elucidated.
Thus we examined the effects of the mutant PTEN genes on the sensitivity of the breast cancer
cells to the combination of doxorubicin and rapamycin treatment. The cells transfected with
the mutant PTEN genes were more sensitive to rapamycin than the cells transfected with WT
or the empty EGFPc2 vector. The effects of rapamycin were seen over a broad dose range (1
to 1000 nM). Rapamycin also synergistically suppressed (decreased) the IC50 for doxorubicin
in the cells transfected with the PTEN mutants.
In this manuscript, the effects of introduction of WT and mutant PTEN genes on the
clonogenicity and sensitivity of MCF-7 cells to doxorubicin, 4HT and rapamycin have been
examined. Introduction of additional copies of WT PTEN into PTEN-positive MCF-7 cells,
inhibited initial colony formation in the absence of doxorubicin or rapamycin when compared
to MCF-7 cells transfected with mutant PTEN or the control EGFPc2 plasmid. While the WT
PTEN gene reduced the colony forming ability in the absence of doxorubicin or rapamycin, it
did not alter the growth rate or sensitivity to either doxorubicin or rapamycin in the pools of
stably transfected PTEN WT cells which were isolated and expanded in the presence of G418.
The two different assays differed in the time frames of the experiments; the initial colony
formation assays were performed over a 3 to 4 week period while the growth assays were
performed over a 5 day time period on the stably transfected cells. Furthermore, once the cells
are selected to grow, they may be able to survive in the presence of higher levels of PTEN
activity. Alternatively increased PTEN levels may be suppressed in the cells which survive
and proliferate. These two possibilities are a common occurrence in gene transfer experiments
and are under further investigation.
Introduction of PTEN mutants lacking lipid and protein or lipid phosphatase activity enhanced
the growth of the breast cancer cells in the presence of chemotherapeutic drugs. Interfering
with the phosphatase activity of PTEN also resulted in higher levels of activated Akt detected
in the serum and hormone deprived samples and prolonged detection of activated Akt after
FBS stimulation in the breast cancer cells transfected with PTEN mutant than in the empty
vector transfected cells. Akt has been reported to slow the growth rate of certain cells as well
as increase the cell size (Jin et al., 2005). The phosphatase deficient PTEN transfected cells,
which displayed elevated Akt signaling proliferated slower than the empty vector transfected
cells. Phosphatase deficient PTEN mutants also decreased the sensitivity of MCF-7 cells to
doxorubicin and increased their sensitivity to rapamycin when compared with the empty vector
transfected cells.
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Inheritance of a PTEN mutant lacking both lipid and protein phosphatase activity conferred
more resistance to doxorubicin than the lipid phosphatase deficient PTEN mutant, indicating
that interfering with both lipid and protein phosphatase activities of PTEN were important in
terms of therapeutic resistance. Also rapamycin exerted a greater degree of inhibition of the
doxorubicin IC50 in cells transfected with the lipid and protein phosphatase deficient PTEN
gene than in the cells transfected with the lipid phosphatase PTEN mutant.
PTEN activity is critically involved in regulation of downstream Akt activity which is
important in drug sensitivity. Altering normal PTEN activity by some PTEN mutations may
lead to drug resistance. Augmented Akt activity may increase resistance to doxorubicin. In
fact, published reports (Clark et al., 2002, Tokunaga et al., 2006) and our own preliminary data
indicate that ectopic Akt expression increases the resistance of MCF-7 breast cancer cells to
doxorubicin and tamoxifen.
These results are relevant to potential cancer therapies as the PTEN gene is frequently mutated
in human cancer. Mutations occur which either delete the PTEN gene or alter its activity.
Sometimes these mutations actually make the cells sensitive to Akt and mTOR inhibitors as
the growth of the cells becomes dependent upon elevated Akt levels (DeGraffenried et al.,
2006). Furthermore, epigenetic mechanism may silence PTEN transcription and transcriptional
mechanisms may alter the splicing of PTEN mRNA transcripts. Restoration of WT PTEN
activity or inhibition of Akt activity are key strategies to prevent chemoresistance. PI3K, PDK,
Akt and downstream mTOR inhibitors have been developed and evaluated in clinical trials.
Unfortunately, PI3K (LY294002) and Akt (A-443654) inhibitors tend to have associated
toxicity and specificity problems (Luo et al., 2005., Martelli et al., 2007). This may not be that
surprising as this pathway regulates numerous pathways involved in cell cycle progression,
growth and apoptosis as well as glucose homeostasis.
Some point mutations eliminating PTEN phosphatase activity such as the C124S and G129E,
without gene deletion, may result in PTEN genes which serve as DN mutants suppressing the
normal PTEN activity encoded by the remaining endogenous WT allele. These PTEN mutants
may serve to stimulate chemo- and hormonal-resistance of certain tumors. Identification of
such mutations may become important in breast cancer therapy as it has been shown that the
loss of PTEN activity is associated with Herceptin resistance (Nagata et al., 2007). Only one
allele of PTEN may be mutated in many human cancers. Interesting both the C124S and G129E
PTEN mutations were originally observed in CS patients and postulated to act as DN mutations
in human cancer and other diseases (Lian et al., 1997).
While inhibition of the lipid phosphatase activity of PTEN was sufficient to induce resistance
of the cells to doxorubicin, inhibition of the protein phosphatase activity of PTEN further
increased chemoresistance indicating that the protein targets of PTEN are also important in its
effects as a tumor suppressor. Further elucidation of these targets of PTEN may aid in the
identification of suitable targets for therapeutic intervention. Fak and Shc are known targets
of the protein phosphatase activity of PTEN (Steelman et al., Li et al., 1997, Li et al., 1997,
Nimwegen et al., 2006, Tamura et al., 1998). Elucidating the protein substrates of the PTEN
phosphatase could reveal important targets for therapeutic intervention.
The PTEN phosphatase deficient mutant transfected cells were also more resistant to the
induction of cellular senescence induced by doxorubicin. While differences in the induction
of cellular senescence in the PTEN WT and mutant transfected cells were not observed in the
absence of doxorubicin, the PTEN mutant cells, which expressed higher levels of activated
Akt than the PTEN WT cells were more resistant to the induction of cellular sensescence
mediated by doxorubicin. Thus altering the PTEN genetic status in human cancer may inhibit
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the ability of chemotherapeutic drugs to induce cellular senescence and allow the outgrowth
of resistant clones which result in metastasis and death of the cancer patient.
Summary
Breast cancer is a common disease which affects women and men in the prime of their lives.
Unfortunately there is no common magic bullet which can effectively cure all breast cancers.
Breast cancer arises from many diverse genetic mechanisms. Frequently breast cancer becomes
resistant to various therapies and residual, dormant, senescent, drug resistant breast cancer cells
resume their growth and often metastize to other sites. At this point, therapeutic options are
limited and we desperately need more effective treatments. This chapter has focused on the
key roles that the PI3K/PTEN/Akt/mTOR pathway plays in breast cancer drug resistance and
induction of cellular sensecence. Furthermore, breast cancer cells which proliferate in response
to this pathway may have an Achilles heel and are highly sensitive to mTOR inhibitors.
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Figure 1. Overview of PI3K/PTEN/Akt/mTOR and Raf/MEK/ERK Pathways
The PI3K/PTEN/Akt/mTOR and Raf/MEK/ERK PI3K/PTEN/Akt/mTOR and pathways are
regulated by upstream growth factor and mitogen receptors as well as Ras and various kinases.
Many kinases serve to phosphorylate S/T and Y residues on Raf and S/T residues on Akt. Some
of the Raf phosphorylation events serve to enhance its activity (shown by a black P in a white
circle) whereas others serve to inhibit its activity (shown by a white P in a black circle.
Moreover there are phosphatases such as PP2A, PTEN, SHIP and PHLPP, which remove
phosphates on certain regulatory residues on Raf, MEK, ERK, PtdIns(3,4,5)P3 and Akt as well
as other signaling molecules. The PI3K/Akt pathway is also activated after receptor ligation.
Akt and ERK have many downstream targets which serve to regulate cell growth and apoptosis.
Some of the downstream transcription factors regulated by these pathways are indicated in
diamond shaped outlines.
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Figure 2. Effects of PI3K/PTEN/Akt/mTOR and Raf/MEK/ERK Pathways on Apoptotic Circuity
Growth factors can induce multiple signal transduction pathways which can effect the
expression of apoptotic molecules by transcriptional and post-transcriptional mechanisms. The
effects of the PI3K/PTEN/Akt/mTOR and Raf/MEK/ERK pathways are often counterbalanced
by JNK and GSK-3β which can serve to promote apoptosis.
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Figure 3. Sites of Gene Mutation/Amplification which Can Result in Activation of the PI3K/PTEN/
Akt/mTOR and Raf/MEK/ERK Cascades
Amplification of HER2 is observed in 25 to 30% of breast cancer patients which can result in
activation of both the PI3K/PTEN/Akt/mTOR and Raf/MEK/ERK cascades. Ras is mutated
in approximately 35% of human cancers. B-Raf and Raf-1 are also mutated in certain human
cancers. The PI3K/PTEN/Akt/mTOR pathway is also activated in breast cancer due to
mutations at PI3K, PTEN and Akt as well as mutations at upstream receptors. Abnormal Akt
activation is associated with a poorer prognosis for breast cancer and resistance to chemo-
hormonal therapy.
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Figure 4. Targeting Signal Transduction Pathways in Breast Cancer
Potential sites of action of small molecular weight inhibitors and cytotoxic antibodies are
indicated. In some cases inhibitors will suppress growth, apoptotic and cell cycle regulatory
pathways. This diagram serves to illustrate the concept that targeting PI3K/PTEN/Akt/mTOR
and Raf/MEK/ERK pathways can have dramatic effects on many growth regulatory molecules.
Proteins inactivated by S/T phosphorylation induced by the PI3K/PTEN/Akt/mTOR and Raf/
MEK/ERK pathways are shown in black circles with white P in a black circle.
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Figure 5. Induction of Cellular Senescence by Doxorubicin in the Presence and Absence of DN
PTEN
MCF-7 cells transfected with the empty vector (EGFP-c2) as well as various PTEN constructs
were seeded into 6 well plates containing cover slips and different concentrations of
doxorubicin and cultured for 4 days. Induction of cellular senescence was determined by a β-
galactosidase assay with X-gal as a substrate. In this figure, photographs of MCF/EGFP-c2
and MCF/PTEN(C124S) cells cultured in the presence and absence of 100 nM doxorubicin
and subsequently stained for β-galactosidase activity are presented. Fixed cells were
photographed under a Nikon Eclipse E600 microscope under bright field settings.
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